New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For SNY;BMY;MRK;JNJ;NVS;ABT;CELG;PFE;SHPG;GSK From The Last 14 Days
Check below for free stories on SNY;BMY;MRK;JNJ;NVS;ABT;CELG;PFE;SHPG;GSK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
September 5, 2014
10:05 EDTCELG, JNJOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Actavis (ACT) initiated with a Buy at ISI Group... Akamai (AKAM) initiated with a Buy at UBS... Alexion (ALXN) initiated with a Buy at SunTrust... Allegion (ALLE) initiated with a Buy at Buckingham... Allergan (AGN) initiated with a Buy at ISI Group... Aviat Networks (AVNW) initiated with a Neutral at H.C. Wainwright... Celgene (CELG) initiated with a Buy at SunTrust... EZCORP (EZPW) initiated with a Hold at Jefferies... Eaton (ETN) initiated with a Neutral at Buckingham... Emerson (EMR) initiated with a Neutral at Buckingham... HMS Holdings (HMSY) initiated with an Overweight at Stephens... Incyte (INCY) initiated with a Buy at SunTrust... Ingersoll-Rand (IR) initiated with a Neutral at Buckingham... Insmed (INSM) initiated with an Outperform at Cowen... Intercept (ICPT) initiated with an Outperform at Cowen... Johnson & Johnson (JNJ) initiated with an Outperform at BMO Capital... Lennox (LII) initiated with a Neutral at Buckingham... Mylan (MYL) initiated with a Hold at ISI Group... Orion Engineered Carbons (OEC) initiated with a Buy at Goldman... Parker-Hannifin (PH) initiated with a Buy at Buckingham... Pentair (PNR) initiated with a Neutral at Buckingham... Pharmacyclics (PCYC) initiated with a Neutral at SunTrust... Rockwell Automation (ROK) initiated with a Neutral at Buckingham... Sabre (SABR) initiated with an Outperform at Oppenheimer... Santander Consumer (SC) initiated with a Buy at Jefferies... Springleaf (LEAF) initiated with a Buy at Jefferies... Susser Petroleum (SUSP) initiated with a Neutral at Credit Suisse... Teva (TEVA) initiated with a Buy at ISI Group... Valeant (VRX) initiated with a Buy at ISI Group... WESCO (WCC) initiated with a Neutral at Buckingham... Watsco (WSO) initiated with a Neutral at Buckingham... Weyerhaeuser (WY) initiated with a Neutral at JPMorgan... World Acceptance (WRLD) initiated with a Hold at Jefferies.
08:41 EDTJNJJohnson & Johnson initiated with an Outperform at BMO Capital
Target $118.
08:39 EDTMRKMerck Keytruda sales to reach $5B in 2018, says BMO Capital
Subscribe for More Information
05:46 EDTABTDexCom competition closer after Abbott approval, says Piper Jaffray
Subscribe for More Information
September 4, 2014
17:56 EDTCELGCelgene initiated with a Buy at SunTrust
Target $121.
16:05 EDTPFEPfizer granted orphan status for sickle cell disease drug
Subscribe for More Information
15:16 EDTMRKMerck receives accelerated approval of Keytruda
Subscribe for More Information
11:05 EDTJNJJ&J unit Janssen receives orphan status for whipworm treatment
Subscribe for More Information
09:02 EDTMRKMerck's relebactam granted QIDP, fast track designations by FDA
Merck announced that the U.S. Food and Drug Administration has designated relebactam -- previously known as MK-7655 -- the companyís investigational beta-lactamase inhibitor, as a Qualified Infectious Disease Product with designated Fast Track status. The QIDP and Fast Track designations apply to intravenous use of relebactam for the treatment of complicated urinary tract infections, complicated intra-abdominal infections and hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia. Relebactam is an investigational, class A and C, beta-lactamase inhibitor that is being evaluated in combination with imipenem/cilastatin in ongoing Phase 2 clinical trials for the treatment of complicated urinary tract infections and complicated intra-abdominal infections. In preclinical studies, relebactam administered in combination with imipenem/cilastatin demonstrated antibacterial activity against a broad range of Gram-negative and beta-lactam-resistant pathogens. Merck plans to initiate Phase 3 studies with relebactam in combination with imipenem/cilastatin in 2015.
08:02 EDTBMYTeva launches generic Baraclude in U.S.
Teva (TEVA) announces the launch of the generic equivalent to Baraclude tablets in the U.S. Teva was first to file, making the product eligible for 180 days of marketing exclusivity. Baraclude is marketed by Bristol-Myers Squibb (BMY).
07:33 EDTCELGCelgene announces REVLIMID Phase III FIRST trial met primary endpoint
Subscribe for More Information
07:23 EDTPFEAstraZeneca called for inversion clamp down as part of defense, WSJ says
Amid its defense against an unsolicited takeover bid from rival Pfizer (PFE), AstraZeneca (AZN) hired advisers with close ties to the Obama administration, who made calls to senior administration officials urging a clamp down on tax inversions, said The Wall Street Journal, citing people familiar with the previously undisclosed calls. Reference Link
07:21 EDTMRKMedidata can obtain major new platform customers, says Stifel
Noting that Medidata (MDSO) partners with Veeva, Stifel believes that a number of Veeva (VEEV) customers could become Medidata platform customers, especially if they already use Medidata for R&D and clinical trial solutions. The firm identifies Merck (MRK), Gilead (GILD), and Teva (TEVA) as companies that may become platform clients for Medidata. Stifel keeps a $55 price target and Buy rating on Medidata.
05:23 EDTJNJJohnson & Johnson to fast-track development of Ebola combination vaccine regimen
Subscribe for More Information
September 3, 2014
17:25 EDTMRKMerck management to meet with SunTrust
Subscribe for More Information
12:49 EDTSNYSanofi reports Dengue vaccine candidate achieves its phase 3 primary endpoint
Sanofi Pasteur, the vaccines division of Sanofi, announced that the final landmark phase 3 efficacy study of its dengue vaccine candidate in Latin America successfully achieved its primary clinical endpoint. Results showed an overall significant reduction of 60.8% of dengue disease cases in children and adolescents 9-16 years old after a three-dose vaccination schedule. Importantly, efficacy was observed against each of the four dengue serotypes. Additional observations of the results showed a clinically important reduction by 80.3% in the risk of hospitalization due to dengue during the study. The results also showed in the study population an efficacy against dengue haemorrhagic fever, the severe form of dengue, which is consistent with the results released from Sanofiís phase 3 dengue study in Asia. Lastly, the results suggest better protection in case of prior exposure to dengue.
12:19 EDTSHPGOptions with increasing implied volatility
Subscribe for More Information
11:30 EDTPFEPfizer has conference call hosted by Bernstein
Subscribe for More Information
09:32 EDTABTAbbott receives CE Mark for FreeStyle Libre
Subscribe for More Information
05:43 EDTNVSNovartis Gilenya data redefining MS treatment goals
Novartis announced that new analyses to be presented at the Joint ACTRIMS-ECTRIMS Meeting in Boston, MA from September 10-13, will add to the growing evidence confirming the importance of redefining treatment goals in multiple sclerosis, or MS. The goal of MS treatment is to have 'no evidence of disease activity' or 'NEDA', which is currently defined as no evidence of relapses, MRI lesions and disability progression. New data to be presented will reinforce the clinical relevance of brain shrinkage and highlight the benefit of including it as a fourth key measure of MS in the definition of NEDA. In addition, other analyses will show that patients treated with Gilenya were more likely to achieve NEDA based on assessment of these four key measures, including MS-related brain shrinkage, than those on placebo. New Gilenya analyses will show how brain shrinkage is associated with future long-term disability progression in patients with MS and that patients with relapsing MS treated with Gilenya had lower rates of brain shrinkage that importantly were sustained over time. The findings will also provide further evidence of the high efficacy of Gilenya on MS disease activity across four key measures.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use